17β‐estradiol promotes the progression of temporomandibular joint osteoarthritis by regulating the FTO/IGF2BP1/m6A‐NLRC5 axis
Immunity, Inflammation and Disease · 2024
DOI: 10.1002/iid3.1361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2024. Verfasst von Xintong Xue und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Estradiol, Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Osteoarthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Science and Technology Commission Sailing Program, National Natural Science Foundation of China, Fundamental Research Plan of Shanghai Stomatological Hospital.
Abstract (Originalsprache)
Background
Temporomandibular joint osteoarthritis (TMJOA) is a degenerative cartilage disease. 17β‐estradiol (E2) aggravates the pathological process of TMJOA; however, the mechanisms of its action have not been elucidated. Thus, we investigate the influence of E2 on the cellular biological behaviors of synoviocytes and the molecular mechanisms.
Methods
Primary fibroblast‐like synoviocytes (FLSs) isolated from rats were treated with TNF‐α to establish cell model, and phenotypes were evaluated using cell counting kit‐8, EdU, Tanswell, enzyme‐linked immunosorbent assay, and quantitative real‐time PCR (qPCR). The underlying mechanism of E2, FTO‐mediated NLRC5 m6A methylation, was assessed using microarray, methylated RNA immunoprecipitation, qPCR, and western blot. Moreover, TMJOA‐like rat model was established by intra‐articular injection of monosodium iodoacetate (MIA), and bone morphology and pathology were assessed using micro‐CT and H&E staining.
Results
The results illustrated that E2 facilitated the proliferation, migration, invasion, and inflammation of TNF‐α‐treated FLSs. FTO expression was downregulated in TMJOA and was reduced by E2 in FLSs. Knockdown of FTO promoted m6A methylation of NLRC5 and enhanced NLRC5 stability by IGF2BP1 recognition. Moreover, E2 promoted TMJ pathology and condyle remodeling, and increased bone mineral density and trabecular bone volume fraction, which was rescued by NLRC5 knockdown.
Conclusion
E2 promoted the progression of TMJOA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China.
- Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Shanghai, China.
- Department of Endodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China.
- Department of Prosthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China.
- Department of Implantology, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China.
ORCID-Profile: Yan Xu
Förderung
- Shanghai Science and Technology Commission Sailing Program
- National Natural Science Foundation of China
- Fundamental Research Plan of Shanghai Stomatological Hospital
Zitieren
APA
Xue, X., Li, C., Chen, S., Zheng, Y., Zhang, F., & Xu, Y. (2024). 17β‐estradiol promotes the progression of temporomandibular joint osteoarthritis by regulating the FTO/IGF2BP1/m6A‐NLRC5 axis. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1361
Vancouver
Xue X, Li C, Chen S, Zheng Y, Zhang F, Xu Y. 17β‐estradiol promotes the progression of temporomandibular joint osteoarthritis by regulating the FTO/IGF2BP1/m6A‐NLRC5 axis. Immunity, Inflammation and Disease. 2024. doi:10.1002/iid3.1361
BibTeX
@article{Xue2024,
author = {Xue, Xintong and Li, Changyi and Chen, Shuang and Zheng, Yan and Zhang, Fan and Xu, Yan},
title = {17β‐estradiol promotes the progression of temporomandibular joint osteoarthritis by regulating the FTO/IGF2BP1/m6A‐NLRC5 axis},
journal = {Immunity, Inflammation and Disease},
year = {2024},
doi = {10.1002/iid3.1361}
}
EUVIMED